Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.67 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | TNF | P01375 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | G6PD | P11413 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845827 | 0.93 | RECQL (0.67) | RECQLMDM2ALDH1A1MEN1KMT2A | |
| SCHEMBL27411452 | 0.89 | ALDH1A1 (0.67) | RECQLMDM2ALDH1A1MEN1KMT2A | |
| SCHEMBL16028621 | 0.89 | ATM (0.71) | RECQLMDM2ALDH1A1MEN1KMT2A | |
| SCHEMBL16076188 | 0.88 | BRDT (0.71) | RECQLMDM2ALDH1A1MEN1KMT2A | |
| SCHEMBL22800992 | 0.87 | RECQL (0.62) | RECQLMDM2ALDH1A1MEN1KMT2A | |
| SCHEMBL22800983 | 0.86 | ALDH1A1 (0.66) | RECQLMDM2ALDH1A1MEN1KMT2A | |
| SCHEMBL6348692 | 0.86 | BRAF (0.72) | ALDH1A1MEN1KMT2ABRAFMAPK1 | |
| SCHEMBL555082 | 0.86 | BRAF (0.72) | ALDH1A1MEN1KMT2ABRAFMAPK1 | |
| SCHEMBL22800918 | 0.85 | HPGD (0.81) | RECQLMDM2ALDH1A1MEN1KMT2A | |
| SCHEMBL637424 | 0.85 | ALDH1A1 (0.76) | RECQLMDM2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262044-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-22 | — | — | US | disclosed |
| EP-3262044-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135199-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-09-01 | — | — | WO | disclosed |
| EP-3061761-A1 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-08-31 | — | — | EP | disclosed |
| CN-102807568-B | Thiadiazoles derivative class DPP-IV inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-102807568-A | Thiadiazole derivative DPP-IV (dipeptidyl peptidase IV) inhibitor | JIANGSU CHIA TAI TIANQING PHAR | 2012-12-05 | — | — | CN | disclosed |
| EP-1404675-B1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK AS (DK) | 2008-03-12 | — | — | EP | disclosed |
| EP-1690864-B1 | TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALLING | CELL THERAPEUTICS INC (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7247630-B2 | Uses of tricyclic compounds | CELL THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1347976-A2 | TRICYCLIC PURINE COMPOUNDS AND THEIR ANALOGS AS INHIBIOTRS OF CYTOKINE SIGNALLING | CELL THERAPEUTICS, INC. (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030162801-A1 | Tricyclic compounds and their uses | GONG BAOQING (US) | 2003-08-28 | — | — | US | disclosed |
| US-6586429-B2 | For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders | CELL THERAPEUTICS, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002068421-A2 | TRICYCLIC COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALING | CELL THERAPEUTICS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-20020103211-A1 | TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES | CELL THERAPEUTICS, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CELL THERAPEUTICS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162801-A1 | Tricyclic compounds and their uses | NFATC1, MAVS, STAT3 | RECQL 2658/4885MDM2 825/4885ALDH1A1 3429/4885 |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CCR10, IL1RN, CCR1 | RECQL 3796/4885MDM2 3219/4885ALDH1A1 919/4885 |
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | RECQL 1699/4885MDM2 4331/4885ALDH1A1 285/4885 |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | RECQL 3307/4885MDM2 3167/4885ALDH1A1 55/4885 |
| US-20020103211-A1 | TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES | XDH, MAVS, TPX2 | RECQL 1427/4885MDM2 3170/4885ALDH1A1 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.